Disc Medicine, Inc. (IRON)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$79.23-0.18%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IRON
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -6.8% |
| Our one-year growth estimate | diamond | Not available |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IRON — capital allocation — SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 193…
Dated 2026-06-30
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISC MEDICINE, INC. Date: June 30, 2026 By: /s/ John Quisel, J.D., Ph.D Name: John Quisel, J.D., Ph.D. Title: President and Chief Executive Officer
Why it matters: Earnings results can show if the company is on track. Positive results can boost stock performance.
Watch forEarnings report shows revenue growth exceeding 10% year over year.
Also watch forEarnings report shows revenue decline or flat growth year over year.
Why it matters: Maintaining a strong capital position is crucial for funding operations and growth. Changes can signal financial health.
Worry ifManagement says cash reserves are up. They also had successful fundraising efforts.
Less concerning ifManagement says cash reserves are down or there are problems getting funding.
Why it matters: Getting the workforce in line with goals helps operations run better. This can make investors happier.
Supportive ifManagement says they have a score over 60% for aligning the workforce with goals.
Worry ifThe score is still below 40% and has not changed much.
Why it matters: Initial data will show how well DISC-3405 works for polycythemia vera and sickle cell.
Supportive ifEarly data from the Phase 2 study shows good results for polycythemia vera.
Worry ifInitial data shows no effects or safety issues in the Phase 2 study of DISC-3405.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$142 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $414 loss on $10,000 · 4.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,055 loss on $10,000 · 40.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Initial data will show how well DISC-3405 can treat polycythemia vera.
Supportive ifInitial data from the RESTORE-PV study shows good results.
Worry ifEarly data from the RESTORE-PV study shows bad results and safety problems.
Why it matters: This meeting will explain the future for selcodebart. Good feedback could lead to key growth.
Supportive ifThe FDA gave good feedback during the end-of-Phase 2 meeting for selcodebart.
Worry ifThe FDA gave bad feedback during the end-of-Phase 2 meeting for selcodebart.
Why it matters: This data helps us understand how well DISC-0974 works for anemia.
Watch forPositive data at ASCO shows that patients feel better from anemia.
Also watch forData at ASCO shows no improvement or bad results for DISC-0974.
Why it matters: Top results will show if bitopertin can get approval. This matters for the company.
Supportive ifTopline data from the APOLLO trial shows good results. This suggests a chance for approval.
Worry ifTopline data shows bad results. This points to problems for bitopertin's approval.
Why it matters: Topline data will show if bitopertin can help with a CRL response and approval.
Supportive ifTopline data from the Phase 3 APOLLO study shows good results for bitopertin in EPP.
Worry ifTopline data from the APOLLO study shows bad results or does not meet expectations.
Why it matters: A strong capital position is important for funding operations and growth. Changes can affect financial health.
Worry ifManagement says the capital position is better. It has a score above 60%.
Less concerning ifThe capital position score is below 40% and has not improved.